High-Dose Estrogen for Acute Abnormal Uterine Bleeding
For acute AUB requiring emergency treatment, administer intravenous conjugated estrogens (Premarin) 25 mg IV slowly, repeated in 6-12 hours if necessary, which stops bleeding in 72% of cases. 1, 2
Emergency IV Estrogen Protocol
Dosing and Administration:
- Give 25 mg conjugated estrogens IV or IM (IV preferred for faster response) 1
- Inject SLOWLY to prevent flushing 1
- Repeat dose in 6-12 hours if bleeding continues 1
- Bleeding cessation occurs in approximately 72% of patients within this timeframe 2
Compatibility Requirements:
- Compatible with normal saline, dextrose, and invert sugar solutions 1
- NOT compatible with protein hydrolysate, ascorbic acid, or acidic pH solutions 1
- If adding to existing infusion, inject into tubing just distal to infusion needle 1
Oral High-Dose Estrogen Alternatives
For patients not requiring IV therapy but needing rapid control:
- High-dose estrogen-progestin oral contraceptives can be used for severe bleeding 3
- Oral estrogen is an alternative initial treatment option for severe bleeding in hemodynamically stable patients 3
- The CDC recommends low-dose COCs or estrogen for 10-20 days for heavy/prolonged bleeding during contraceptive use 4
Critical Clinical Context
When to Use IV Estrogen:
- Acute bleeding episodes causing hemodynamic instability 5, 3
- Bleeding saturating a large pad/tampon hourly for at least 4 hours 6
- Failure of initial oral management 5
Mechanism and Efficacy:
- IV Premarin was effective across multiple endometrial pathologies including secretory, proliferative, menstrual, polypoid, cystic hyperplasia, and endometritis 2
- Works by rapidly increasing estrogen levels to stabilize endometrium 1
- Indicated for short-term use only as temporary measure 1
Essential Precautions
Before Administration:
- Rule out pregnancy in all reproductive-age women 6
- Confirm absence of organic pathology (malignancy, structural lesions) 1
- Assess for thromboembolic contraindications, as IV estrogen carries increased thrombosis risk 7
- Consider curettage for patients with hypovolemia or risk factors for endometrial cancer 5
Common Pitfall:
- Do not use IV estrogen as first-line for chronic repetitive bleeding—reserve for acute episodes only 5
- This is NOT a long-term solution; transition to appropriate maintenance therapy after acute control 1
Post-Acute Management Transition
After bleeding control, initiate maintenance therapy based on patient needs: